AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 3266005
Drug: HbOC (after
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HbOC (after second dose at 4 months)
Trial: 3266005
Drug: HbOC (after
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HbOC (after third dose at 6 months)
Trial: 30213449
Drug: Apalutamide (240
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apalutamide (240 mg oral per day) plus androgen deprivation therapy
Trial: 28818054
Drug: Rocuronium 0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rocuronium 0.3 mg/kg IV
Trial: 26202168
Drug: Tomato sauce
RxNorm normalized name: Nutritional Supplement Oral Food, Solid [DIETARY SPECIALTIES TOMATO SAUCE]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tomato sauce (142-198 g/d or 5-7 ounces/d)
Trial: 26202168
Drug: Vegetable juice
RxNorm normalized name: Vegetable Juice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vegetable juice (325-488 ml/d or 11-16.5 fluid ounces/d)
Trial: 26202168
Drug: Lycopene-restricted control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lycopene-restricted control group (< 5 mg lycopene/d)
Trial: 24286114
Drug: Sodium oxybate
RxNorm normalized name: Sodium Oxybate
DrugBank: Sodium oxybate (DB09072)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium oxybate (SXB) 4.5 g/night (administered in 2 equally divided doses), with possible increases to 9 g/night or reductions to 4.5 g/night.
Trial: 21384334
Drug: Two doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two doses of adjuvanted influenza A/09/H1N1 vaccine in patients with inflammatory rheumatic diseases
Trial: 21384334
Drug: One dose
RxNorm normalized name: Next Choice One Dose
DrugBank: Levonorgestrel (DB00367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: One dose of adjuvanted influenza A/09/H1N1 vaccine in healthy controls
Trial: 21384334
Drug: Baseline antibody
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baseline antibody levels in patients and controls
Trial: 21384334
Drug: First dose
RxNorm normalized name: Cow first milk
DrugBank: Bos taurus colostrum (DB19249)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: First dose response in both groups
Trial: 16616012
Drug: Omega-3 fatty
RxNorm normalized name: Omega-3 fatty acid
DrugBank: Omega-3 fatty acids (DB11133)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omega-3 fatty acids (585 mg of docosahexaenoic acid and 225 mg of eicosapentaenoic acid)
Trial: 8839521
Drug: Oral transmucosal
RxNorm normalized name: Thrive, 2 mg oral transmucosal gum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral transmucosal fentanyl citrate (OTFC) 10 to 15 micrograms/kg
Trial: 8839521
Drug: Intramuscular meperidine,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular meperidine, promethazine, and chlorpromazine (MPC) 2 mg/kg meperidine, 0.5 mg/kg promethazine, 0.5 mg/kg chlorpromazine
Trial: 1610630
Drug: 20 ml
RxNorm normalized name: Exact-Med, 20 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 ml kg‐1 of 4% glucose and 0.18% saline (group II)
Trial: 23088514
Drug: 30 g/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 g/day of yellow passion fruit peel flour for two months
Trial: 21243915
Drug: 1xRDA MMS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1xRDA MMS preparation (14 vitamins and minerals)
Trial: 21243915
Drug: 2xRDA MMS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2xRDA MMS preparation
Trial: 21243915
Drug: Pooled effect
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pooled effect of MMS preparations
Trial: 21243915
Drug: 1xRDA MMS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1xRDA MMS preparation
Trial: 17379121
Drug: 3xED(95) bolus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3xED(95) bolus dose of cisatracurium at induction
Trial: 17379121
Drug: Continuous infusion
RxNorm normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusion of cisatracurium during the entire procedure
Trial: 15661841
Drug: Saline (sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline (sodium chloride 308 mmol/l)
Trial: 12039705
Drug: Pulse of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pulse of insulin (0.03 U/kg s.c.) and dexamethasone (2 mg i.v.) with transient hyperglycemia
Trial: 12039705
Drug: Insulin (0.03
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin (0.03 U/kg and 0.06 U/kg) with dexamethasone without transient hyperglycemia
Trial: 12039705
Drug: Pulse of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pulse of insulin and glucose without dexamethasone
Trial: 10534548
Drug: Steroid injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Steroid injection (25 mg/ml prednisolone acetate)
Trial: 1971118
Drug: 0.37 mg
RxNorm normalized name: menthol 0.37 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.37 mg alprazolam
Trial: 394279
Drug: Diclofenac sodium
RxNorm normalized name: Diclofenac Sodium
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Diclofenac sodium (50 mg, rising to 150 mg per day)
Trial: 26053030
Drug: Atazanavir (HIV-1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atazanavir (HIV-1 protease inhibitor)
Trial: 22193796
Drug: Antipsychotics with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antipsychotics with high risk of causing metabolic abnormalities
Trial: 22193796
Drug: Antipsychotics with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antipsychotics with medium risk of causing metabolic abnormalities
Trial: 17351694
Drug: Manual therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Manual therapy (twice weekly)
Trial: 9029748
Drug: Fluvoxamine (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluvoxamine (50 mg for 1 day and 100 mg for 6 days)
Trial: 9029748
Drug: Griseofulvin (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Griseofulvin (500 mg for 9 days)
Trial: 7935655
Drug: Intravenous immune
RxNorm normalized name: Intravenous immune globulin (human)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous immune globulin (400 mg/kg)
Trial: 30423449
Drug: Peanut OIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peanut OIT with a maintenance dose of 125 to 250 mg peanut protein
Trial: 23649189
Drug: ixabepilone 16
RxNorm normalized name: Ixabepilone
DrugBank: Ixabepilone (DB04845)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ixabepilone 16 mg/m(2) weekly plus bevacizumab 10 mg/kg Q2W (Arm A: n = 46)
Trial: 23649189
Drug: ixabepilone 40
RxNorm normalized name: Ixabepilone
DrugBank: Ixabepilone (DB04845)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ixabepilone 40 mg/m(2) Q3W plus bevacizumab 15 mg/kg Q3W (Arm B: n = 45)
Trial: 23649189
Drug: paclitaxel 90
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: paclitaxel 90 mg/m(2) weekly plus bevacizumab 10 mg/kg Q2W (Arm C: n = 32)
Trial: 21411446
Drug: Gefitinib plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gefitinib plus simvastatin (GS) 250 mg/d and 40 mg/d respectively
Trial: 21411446
Drug: Gefitinib alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gefitinib alone (G) 250 mg/d
Trial: 21411446
Drug: Gefitinib alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gefitinib alone (G)
Trial: 21411446
Drug: Gefitinib alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gefitinib alone (G) in patients with wild-type EGFR nonadenocarcinomas
Trial: 14981107
Drug: Arm A:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arm A: subcutaneous interferon alfa‐2a (sc‐IFN‐alpha‐2a), subcutaneous interleukin‐2 (sc‐IL‐2), and intravenous (IV) fluorouracil
Trial: 14981107
Drug: Arm B:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arm B: Arm A treatment combined with per oral 13‐cis‐retinoic acid
Trial: 14981107
Drug: Arm C:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arm C: subcutaneous interferon alfa‐2a (sc‐IFN‐alpha‐2a) and IV vinblastine
Trial: 11577945
Drug: Azithromycin 500
RxNorm normalized name: azithromycin 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azithromycin 500 mg/day
Trial: 11577945
Drug: Piroxicam 20
RxNorm normalized name: piroxicam 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Piroxicam 20 mg/day plus Azithromycin 500 mg/day
Trial: 9685820
Drug: iodixanol 320
RxNorm normalized name: IODIXANOL 320mgI/ml INJ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: iodixanol 320 mg I/ml
Trial: 8995474
Drug: iomeprol 300
RxNorm normalized name: Iomeprol 300 MG/1 ML Injection Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: iomeprol 300 mg I/ml
Trial: 8015643
Drug: Levamisole (2-3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levamisole (2-3 mg/kg/day) twice a week for 12 months
Trial: 2603453
Drug: Clindamycin 900
RxNorm normalized name: clindamycin 900 MG in 6 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clindamycin 900 mg q8h admixed with gentamicin 1.5 mg/kg
Trial: 2603453
Drug: Clindamycin 600
RxNorm normalized name: clindamycin 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clindamycin 600 mg q6h with gentamicin 1.5 mg/kg given separately
Trial: 811982
Drug: Prindolol (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prindolol (2 x 5 mg daily)
Trial: 811982
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of prindolol (2 x 5 mg) + clopamide (10 mg)
Trial: 28807045
Drug: Best medical
RxNorm normalized name: calcium polycarbophil
DrugBank: Calcium polycarbophil (DB14684)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Best medical treatment plus renal artery stenting (stent group)
Trial: 28807045
Drug: Best medical
RxNorm normalized name: calcium polycarbophil
DrugBank: Calcium polycarbophil (DB14684)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Best medical treatment (BMT group)
Trial: 22589424
Drug: Daily light
RxNorm normalized name: TITANIUM DIOXIDE 63 mg in 1 mL / ZINC OXIDE 41 mg in 1 mL TOPICAL LOTION [DAILY LIGHT GUARD DEFENSE FLUID BROAD SPECTRUM SPF 30]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily light smokers (3‐9 cigarettes/day)
Trial: 21523384
Drug: Oily vitamin
RxNorm normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oily vitamin D(3) preparation
Trial: 21523384
Drug: Alcoholic vitamin
RxNorm normalized name: Alcohol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alcoholic vitamin D(3) preparation
Trial: 16922663
Drug: Lactose microencapsulated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactose microencapsulated vitamin D(3) 100 000 IU orally at baseline, then 3 monthly (three or more doses)
Trial: 2792664
Drug: Loxiglumide (0.2,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Loxiglumide (0.2, 1.0, or 5.0 mg/kg.h)
Trial: 2792664
Drug: Loxiglumide (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Loxiglumide (1 or 5 mg/kg.h) with an 800-kcal meal
Trial: 2792664
Drug: Loxiglumide (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Loxiglumide (5 mg/kg.h) without caerulein or the test meal
Trial: 24944260
Drug: Droxidopa (100-600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Droxidopa (100-600 mg 3 times daily)
Trial: 15379738
Drug: Entacapone administered
RxNorm normalized name: Entacapone
DrugBank: Entacapone (DB00494)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Entacapone administered with 30 min delay
Trial: 15379738
Drug: Co-administered entacapone
RxNorm normalized name: Entacapone
DrugBank: Entacapone (DB00494)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Co-administered entacapone
Trial: 15379738
Drug: Carbidopa/L-dopa
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbidopa/L-dopa
Trial: 11419239
Drug: Cisatracurium (0.15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisatracurium (0.15 mg.kg‐1 for induction, 0.12 mg.kg‐1.h‐1 for continuous infusion)
Trial: 7954541
Drug: Low-dose combinations
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose combinations of different diuretics (e.g., loop diuretics with thiazides)
Trial: 2570959
Drug: Bovine colostrum
RxNorm normalized name: Bovine Colostrum
DrugBank: Bos taurus colostrum (DB19249)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bovine colostrum with high antibody titre against human rotavirus
Trial: 26011141
Drug: FPHT sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FPHT sodium injection (400 mg PHT acid equivalent)
Trial: 26011141
Drug: FPHT sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FPHT sodium injection
Trial: 26011141
Drug: PHT sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PHT sodium injection (400 mg PHT acid equivalent)
Trial: 21812262
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment of HSCT (Control)
Trial: 20024753
Drug: Self-Administered Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-Administered Therapy
Trial: 17058023
Drug: Cognitive Behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behavioral Therapy (CBT) intervention for weight loss through exercise and diet modification, once weekly for 16 weeks.
Trial: 1851063
Drug: Aldosterone infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aldosterone infusion (3 pmol min‐1 kg‐1)
Trial: 1851063
Drug: Placebo (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (no aldosterone infusion)
Trial: 1851063
Drug: Saline infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline infusion (0.9% NaCl)
Trial: 6794420
Drug: Metoprolol Durules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoprolol Durules 200 mg o.m.
Trial: 26401704
Drug: Phenserine treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phenserine treatment for 12 months
Trial: 26401704
Drug: Phenserine treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phenserine treatment
Trial: 21152932
Drug: 1 ×
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 × CAF (6 mg kg(‐1) body mass caffeine, 1 h before exercise)
Trial: 21152932
Drug: 3 ×
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 × CAF (2 mg kg(‐1) body mass caffeine on three separate occasions during the day)
Trial: 21152932
Drug: PLA (0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PLA (0 mg caffeine)
Trial: 19245438
Drug: PSD502 (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PSD502 (3 actuations of spray each containing 7.5 mg lidocaine and 2.5 mg prilocaine applied 5 min before intercourse)
Trial: 15158628
Drug: Morphine (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine (no open-label)
Trial: 11150914
Drug: Perioperative chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perioperative chemotherapy (periCT) consisting of cyclophosphamide, epidoxorubicin, and 5-fluorouracil
Trial: 11150914
Drug: No perioperative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No perioperative chemotherapy (control)
Trial: 29522648
Drug: Hyoscine hydrobromide
RxNorm normalized name: Hyoscine hydrobromide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyoscine hydrobromide 0.6 mg
Trial: 9205824
Drug: Zamifenacin 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zamifenacin 20 mg
Trial: 8424420
Drug: Erythromycin 200
RxNorm normalized name: ERYTHROMYCIN 200 mg in 2 g TOPICAL POWDER [API E.M. Erythromycin]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythromycin 200 mg intravenously
Trial: 3319642
Drug: High-dose metoclopramide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose metoclopramide infusion
Trial: 31464143
Drug: Vaginal micronized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaginal micronized progesterone capsules
Trial: 28591776
Drug: Nonaqueous mini‐dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonaqueous mini‐dose glucagon (MDG) (150 µg)
Trial: 28591776
Drug: Glucose tablets
RxNorm normalized name: Glucose Tablets Orange Obsolete
DrugBank: Dextrose, unspecified form (DB09341)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Glucose tablets (TABS)
Trial: 16965206
Drug: 4-step treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4-step treatment algorithm (washout period, anti-depressant monotherapy, lithium addition, treatment with a nonselective monoamine oxidase inhibitor, electroconvulsive therapy)
Trial: 16965206
Drug: 4-step treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4-step treatment algorithm
Trial: 9798804
Drug: RBC 400
RxNorm normalized name: Ultratag RBC KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RBC 400 mg b.d. plus clarithromycin 250 mg b.d. and tinidazole 500 mg b.d. for 1 week (RbcCT)
Trial: 9798804
Drug: RBC 400
RxNorm normalized name: Ultratag RBC KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RBC 400 mg b.d. plus clarithromycin 500 mg b.d. for 2 weeks (RbcC)
Trial: 360232
Drug: piracetam (Nootropil)
DrugBank: Piracetam (DB09210)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: piracetam (Nootropil) 2400 mg/day
Trial: 30630559
Drug: Dezocine-remifentanil intravenous
RxNorm normalized name: DEZOCINE
DrugBank: Dezocine (DB01209)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dezocine-remifentanil intravenous anaesthesia
Trial: 30630559
Drug: Midazolam-remifentanil intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam-remifentanil intravenous anaesthesia
Trial: 10997483
Drug: estrogen/glucocorticoid combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: estrogen/glucocorticoid combination
Trial: 1580345
Drug: Short-term group
RxNorm normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Short-term group treatment program for abusive husbands
Trial: 3882059
Drug: High energy
RxNorm normalized name: High energy formula
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High energy feeds (3.6 MJ/L, 87 kcal/100 ml)
Trial: 3882059
Drug: Standard energy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard energy feeds (2.7 MJ/L, 65 kcal/100 ml)
Trial: 26918239
Drug: Pulsed dye
RxNorm normalized name: amaranth dye
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pulsed dye laser (PDL) plus timolol gel 0.05%
Trial: 19370466
Drug: Diclofenac 3%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diclofenac 3% gel followed by ALA-PDT
Trial: 19370466
Drug: Placebo gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo gel followed by ALA-PDT
Trial: 16911579
Drug: Mitral isthmus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mitral isthmus line (ML) recovery
Trial: 15224297
Drug: 18 Gy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 18 Gy radiation dose
Trial: 15224297
Drug: 15 Gy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 Gy radiation dose
Trial: 3915461
Drug: Tenoxicam 1.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tenoxicam 1.2 mg/kg
Trial: 9807845
Drug: Tenoxicam 0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tenoxicam 0.3 mg/kg
Trial: 3915461
Drug: Tenoxicam 0.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tenoxicam 0.6 mg/kg
Trial: 31850931
Drug: GED‐0301 (160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GED‐0301 (160 mg for 12 weeks followed by 40 mg continuously)
Trial: 31850931
Drug: GED‐0301 (alternating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GED‐0301 (alternating placebo with 40 or 160 mg every 4 weeks through week 52)
Trial: 18814099
Drug: Prostanoids, nonselective
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prostanoids, nonselective and selective endothelin-receptor antagonists, phosphodiesterase-V inhibitors
Trial: 16870914
Drug: Inhaled nitric
RxNorm normalized name: nitric oxide Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled nitric oxide (5 ppm) for 21 days or until extubation
Trial: 10893362
Drug: Seratrodast, 40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Seratrodast, 40 mg/d
Trial: 3837566
Drug: Modified holding
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified holding therapy (MHT)
Trial: 24253831
Drug: FF 100
RxNorm normalized name: APAP 325/CAFF 100/ISOMETHEPTENE 65MG CAP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FF 100 μg
Trial: 9570244
Drug: Triple therapy
RxNorm normalized name: MigreLief Triple Therapy with Puracol Caplet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple therapy with metronidazole (500 mg twice daily for 2 weeks), amoxycillin (500 mg three times daily for 2 weeks), and omeprazole (20 mg once daily for 8 weeks)
Trial: 9570244
Drug: Dual therapy
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual therapy with amoxycillin (500 mg three times daily for 2 weeks) and omeprazole (20 mg once daily for 8 weeks)
Trial: 28581818
Drug: linagliptin 5
RxNorm normalized name: linagliptin 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: linagliptin 5 mg a.m. and placebo p.m. (n=8)
Trial: 28581818
Drug: metformin 500
RxNorm normalized name: metformin 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: metformin 500 mg bid (n=8)
Trial: 15198380
Drug: Cyanocobalamin, 1
RxNorm normalized name: Cyanocobalamin, 100 mcg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyanocobalamin, 1 mg daily for 7 days, and 5 mg on the eighth day
Trial: 15198380
Drug: Placebo injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo injection daily for 8 days
Trial: 2499825
Drug: Topical phenytoin
RxNorm normalized name: Phenytoin
DrugBank: Phenytoin (DB00252)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical phenytoin (PHT)